GlassScriptPhysician profile
Richard J Valente
NPI 1760464077
$3,126.03
in general payments reported to CMS, 2019-2025
31 companies · $499 in 2025
The $499 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $917 · 2020: $41.16 · 2021: $145 · 2022: $197 · 2023: $801 · 2024: $526 · 2025: $499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,626 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,626.39 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $508.58 | 2019-2025 | |
| Amgen INC. | $260.80 | 2019-2024 | Repatha |
| Pfizer INC. | $252.07 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $200.00 | 2025 | |
| Abbott Laboratories | $184.91 | 2022-2025 | Jot Dx, Pressurewire, Xience Skypoint |
| E.R. Squibb & Sons, L.L.C. | $178.50 | 2019-2024 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $149.70 | 2023-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $125.07 | 2019 | |
| Inari Medical, INC. | $120.83 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $116.94 | 2019-2025 | Lifevest |
| Lexicon Pharmaceuticals, INC. | $104.78 | 2023 | Inpefa |
| Impulse Dynamics (USA) INC. | $95.25 | 2023 | Optimizer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.85 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $84.83 | 2019-2024 | Farxiga, Brilinta |
| Regeneron Healthcare Solutions, INC. | $82.14 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiva Medical, INC. | $72.01 | 2023-2025 | Cardiva Vascade Mvp Xl Vvcs 10-12f, Cardiva Vascade Mvp Vvcs 6-12f |
| Lantheus Medical Imaging, INC. | $70.12 | 2021 | |
| Medtronic, INC. | $68.87 | 2021-2024 | Corevalve Evolut R |
| Boston Scientific Corporation | $51.79 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $49.97 | 2024 | Voquezna |
| Daiichi Sankyo INC. | $40.00 | 2023-2024 | Injectafer |
| Novo Nordisk INC | $39.87 | 2023 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $39.07 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $32.96 | 2019-2023 | Uptravi, Opsumit |
| Kiniksa Pharmaceuticals International, Plc | $19.55 | 2024 | Arcalyst |
| Atricure, INC. | $19.47 | 2025 | Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System |
| Philips North America LLC | $17.97 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.22 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.19 | 2019 | |
| Irhythm Technologies, INC. | $11.49 | 2020 | |
| Gilead Sciences, INC. | $11.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Valente listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.